Literature DB >> 14748877

Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver.

Yi Xiao1, Jörg Kleeff, Junchao Guo, Amiq Gazdhar, Quan Liao, Paul E Di Cesare, Markus W Büchler, Helmut Friess.   

Abstract

BACKGROUND: Cartilage oligomeric matrix protein (COMP) is the fifth member of the thrombospondin family of extracellular, calcium-binding proteins. It was initially isolated and characterized in cartilage tissue, where it is thought to contribute to the extracellular matrix composition and cell-extracellular matrix interaction. In the present study the expression of COMP was investigated in normal liver (n=19), liver cirrhosis (n=14) and hepatocellular carcinoma (HCC; n=16) tissues, both at the mRNA and protein level. METHODS AND
RESULTS: By northern blot and western blot analysis, COMP was absent or rarely expressed in the normal liver and liver cirrhosis tissues, but significantly overexpressed in HCC tissue samples. The COMP mRNA overexpression in HCC was not related to the clinical stage or tumor grade. By in situ hybridization and immunohistochemistry analysis, COMP mRNA and protein expression were localized within the cytoplasm of the tumor cells.
CONCLUSION: COMP is highly expressed within the tumor cells of HCC, suggesting that COMP might play a role in the pathophysiology of this disease. Copyright 2004 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748877     DOI: 10.1111/j.1440-1746.2003.03268.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma.

Authors:  Gary L Norman; Nikolaos K Gatselis; Zakera Shums; Christos Liaskos; Dimitrios P Bogdanos; George K Koukoulis; George N Dalekos
Journal:  World J Hepatol       Date:  2015-07-18

2.  Cartilage oligomeric matrix protein as a non-invasive biomarker for diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Hala A Abdel-Azeez; Hoda A Elhady; Abeer A Fikry
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 3.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

4.  The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.

Authors:  Qing Yang; Changfeng Sun; Yunjian Sheng; Wen Chen; Cunliang Deng
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

Review 5.  Gene expression profiling for the purposes of biomarker discovery in oral potentially malignant lesions: a systematic review.

Authors:  Ahmad A Abdulmajeed; Camile S Farah
Journal:  Clin Med Insights Oncol       Date:  2013-10-31

Review 6.  Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Stijn Van Hees; Peter Michielsen; Thomas Vanwolleghem
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

7.  HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.

Authors:  Qing Li; Cong Wang; Yufeng Wang; Liankang Sun; Zhikui Liu; Liang Wang; Tao Song; Yingmin Yao; Qingguang Liu; Kangsheng Tu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-19

Review 8.  Cartilage Oligomeric Matrix Protein, Diseases, and Therapeutic Opportunities.

Authors:  Jiarui Cui; Jiaming Zhang
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

9.  Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; Jadranka Milosevic; Kusum Pandit; Ahmi Ben-Yehudah; Yanxia Chu; Thomas Richards; Joshua Sciurba; Michael Myerburg; Yingze Zhang; Anil V Parwani; Kevin F Gibson; Naftali Kaminski
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.